AUTHOR=Sivasubramanian Madhini , Avari Parizad , Gilbert Clare , Doodson Louise , Morgan Kate , Oliver Nick , Shah Pratik TITLE=Accuracy and impact on quality of life of real-time continuous glucose monitoring in children with hyperinsulinaemic hypoglycaemia JOURNAL=Frontiers in Endocrinology VOLUME=Volume 14 - 2023 YEAR=2023 URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1265076 DOI=10.3389/fendo.2023.1265076 ISSN=1664-2392 ABSTRACT=Objective: Continuous glucose monitoring (CGM) is increasingly used for glucose monitoring in people with diabetes, however there are limited data reporting their use in hyperinsulinaemic hypoglycaemia (HH). Here, we evaluate CGM accuracy and its impact on quality of life in children with HH. Methods: Real-time CGM (Dexcom G5 and G6) was used in children with HH aged 0-16years. Data from self-monitoring capillary blood glucose (CBG) and CGM were collected over a period of up to 28days and analysed. Quality of life was assessed by the PedsQL4.0 general module and PedsQL2.0 family impact module, completed by children and their parents/carers before and after CGM insertion. Results: Prospective longitudinal study with data analysed from 40 children. The overall mean absolute relative difference (MARD) between reference glucose and paired CGM values (n=4,928) was 13.0% (Dexcom G5 12.8%, Dexcom G6 13.1%). The proportion of readings meeting %15/15 and %20/20 were 77.3% and 86.4%, respectively, with CEG analysis demonstrating 97.4% of all values in zones A and B. Overall PedsQL child report at baseline and endpoint were 57.6 (50.5 – 75.8) and 87.0 (82.9 – 91.2), and for parents were 60.3 (44.8 – 66.0) and 85.3 (83.7 – 91.3), respectively (both p<0.001). Conclusion: Use of CGM for children with HH is feasible, with clinically acceptable accuracy, particularly in the hypoglycaemic range. Quality of life measures demonstrate significant improvement after CGM use.¬ These data are important to explore use of CGM in rare disease indications, including neonatal and paediatric diabetes, cystic fibrosis and glycogen storage disorders.